One of the underlying mechanisms of the SLFN5-dependent inhibition of cancer invasions, SLFN5 suppresses the expression of MT1-MMP through the inhibition of Akt activity and the subsequent activation of glycogen synthase kinase 3 beta and the deactivation of β-catenin, which is an executor transcription factor in the Wnt/β-catenin cascade [112]. The gene discussed is AKT1; the disease is cancer.